

LC0406F

HepG2+Insulin Cytosol

Cytosolic lysate from that HepG2 cells were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated with 5 µg/ml insulin for 15 minutes prior to harvesting



KINEXUS

Address: 8755 Ash Street, Suite 1
Vancouver, British Columbia,
Canada V6P 6T3

Email: info@kinexus.ca
Phone: 604-323-2547

Production

Product Name Long:	Human hepatic carcinoma HepG2 cells - Insulin-treated - Cytosolic lysate
Production Method:	HepG2 cells were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated with 5 µg/ml insulin for 15 minutes prior to harvesting. Lysates were prepared from scrapped cells that were homogenized by sonication in buffer formulated with 60 mM β-glycerophosphate, pH 7.2, 20 mM MOPS, 20 mM sodium pyrophosphate, 30 mM sodium fluoride, 5 mM EDTA, 3 mM benzamidine, 2 mM EGTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, 10 µM leupeptin, and 5 µM pepstatin A. Cytosolic lysates were prepared following sonication and 30 min ultracentrifugation at 100,000 rpm. Lysates were further diluted in homogenizing buffer at a final concentration of 3 mg/ml.
Amount:	200 µg
Protein Concentration:	3 mg/ml
Storage Stability:	1 year at -70°C

Applications

Lysate Use Description:	For testing antibodies by immunoprecipitation or immunoblotting, and for assays of enzymes.
--------------------------------	---

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit www.kinexusproducts.ca or contact us at 1-888-546-3987